U.S. medical countermeasure development since 2001: A long way yet to go

Biosecurity and Bioterrorism

Volumn 10, Issue 1, 2012, Pages 66-76

  Russell, Philip K ^a   Gronvall, Gigi Kwik ^b  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; SMALLPOX VACCINE; VACCINE;

ANTHRAX; BIOLOGICAL WARFARE; CIVIL DEFENSE; DISASTER PLANNING; GOVERNMENT; HUMAN; INFECTION CONTROL; LEADERSHIP; METHODOLOGY; ORGANIZATION AND MANAGEMENT; REVIEW; SMALLPOX; SOCIAL BEHAVIOR; UNITED STATES;

ANTHRAX; ANTHRAX VACCINES; BIOTERRORISM; CIVIL DEFENSE; COMMUNICABLE DISEASE CONTROL; DISASTER PLANNING; HUMANS; LEADERSHIP; SMALLPOX; SMALLPOX VACCINE; SOCIAL RESPONSIBILITY; UNITED STATES; UNITED STATES DEPARTMENT OF DEFENSE; UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES; VACCINES;

VARIOLA VIRUS;

EID: 84859171775     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2012.0305     Document Type: Review

References (66)

1. U.S. Department of Health and Human Services. Assistant Secretary for Preparedness and Response. The Public Health Emergency Medical Countermeasures Enterprise Review: Transforming the Enterprise to Meet Long-Range National Needs. Washington, DC: U.S. Department of Health and Human Services; August 2010. https://www.medicalcountermeasures. gov/media/1138/mcmreviewfinalcover- 508.pdf. Accessed March 5, 2012.
2. The Bipartisan WMD Terrorism Research Center. Bio-Response Report Card. Washington, DC: Bipartisan WMD Terrorism Research Center; October 2011. http://www.wmd center.org/wp-content/uploads/2011/10/bio-response-reportcard- 2011.pdf. Accessed March 5, 2012.
3. Preston R. The Demon in the Freezer. New York: Random House; 2002.
4. O'Toole T, Mair M, Inglesby TV. Shining light on "Dark Winter." Clin Infect Dis Apr 1 2002;34(7):972-983.
5. Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther 2010;4:71-79.
6. U.S. Department of Health and Human Services. First smallpox vaccine for special populations delivered under Project BioShield [news release]. July 14, 2010. http://www.hhs. gov/news/press/2010pres/07/20100714c.html. Accessed March 5, 2012.
7. Schnirring L. Firm says weakened smallpox vaccine has good safety profile. CIDRAP News November 4, 2008.
8. Adalja AA. Update on smallpox vaccine. Clinicians' Biosecurity News January 8, 2009. http://www.upmc-cbn.org/report-archive/2009/cbnreport-01082009. html. Accessed March 5, 2012.
9. Cangene. Products. 2009. http://www.cangene.com/productsintroduction#. Accessed March 5, 2012.
10. Willman D. House panel wants more details on smallpox drug contract. LA Times December 20, 2011.
11. Ungar R. Is bizare smallpox drug deal Obama administration's next Solyndra? Forbes November 13, 2011.
12. Matheny J, Mair M, Smith B. Cost/success projections for US biodefense countermeasure development. Nat Biotechnol Sep 2008;26(9):981-983.
13. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov Dec 2009;8(12):959-968.
14. Robinson RA. BARDA Strategic Plan 2011-2016. Washington, DC: U.S. Department of Health and Human Services, Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority; 2011. http://www.phe.gov/about/barda/Documents/bardastrategic-plan.pdf. Accessed March 5, 2012.
15. Food and Drug Administration. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. 21 CFR Parts 314 and 601; 2001.
16. Committee on Animal Models for Assessing Countermeasures to Bioterrorism Agents; National Research Council. Animal Models for Assessing Countermeasures to Bioterrorism Agents. Washington, DC: National Academies Press; 2011. http://www.nap.edu/catalog.php?record-id=13233. Accessed March 5, 2012.
17. Gronvall GK, Trent D, Borio L, Brey R, Nagao L. The FDA animal efficacy rule and biodefense. Nat Biotechnol Oct 2007;25(10):1084-1087. (Pubitemid 47538099)
18. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA Feb 28 2001;285(8):1059-1070. (Pubitemid 32176420)
19. U.S. Centers for Disease Control and Prevention. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep 2010 Mar 19;59(10):299.
20. U.S. Department of Health and Human Services. HHS awards BioShield contract for botulism antitoxin [news release]. June 1, 2006. http://archive.hhs.gov/news/press/2006pres/20060601.html. Accessed March 5, 2012.
21. Rusnak JM, Boudreau E, HepburnMJ, Martin JW, Bavari S. Medical countermeasures. In: Dembek ZF, ed. Medical Aspects of Biological Warfare.Washington, DC: Borden Institute; 2007.
22. Statement of Mark A. Elengold, Deputy Director of Operations, Center for Biologics Evaluations and Research, Food and Drug Administration, to the House Committee on Government Reform. Anthrax Vaccine. Washington, DC, 2000.
23. Vander Linden C. USAMRIID employees earn top civilian award. dcmilitary.com 2003. http://ww2.dcmilitary.com/dcmilitary-archives/stories/ 031903/22098-1.shtml. Accessed January 5, 2012.
24. Food and Drug Administration. FDA approves license supplements for anthrax vaccine [news release]. January 31, 2002. http://www.fda.gov/Drugs/ EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm133146.htm. Accessed March 5, 2012.
25. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA May 1 2002;287(17):2236-2252. (Pubitemid 34441940)
26. National Biodefense Science Board. Where Are the Countermeasures? Protecting America's Health from CBRN Threats. 2010. http://www.phe.gov/ Preparedness/legal/boards/nbsb/meetings/Documents/nbsb-mcmreport.pdf. Accessed March 5, 2012.
27. National Biodefense Science Board. Optimizing Industrial Involvement in Medical Countermeasure Development: A Report of the National Biodefense Science Board. February 2010. http://www.phe.gov/Preparedness/legal/boards/nbsb/ Documents/mswgreport.pdf. Accessed March 5, 2012.
28. Remarks by Secretary Kathleen Sebelius. 2011 Public Health Emergency Medical Countermeasures Enterprise Stakeholders Workshop. Washington, DC, 2010.
29. U.S. Department of Defense. Department of Defense Acquisition of Vaccine Production. 2000. http://www.stormingmedia. us/37/3733/A373324.html. Accessed March 5, 2012.
30. Lemon SM, Thaul S, Fisseha S, O'Maonaigh HC, eds. Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military. Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military. Washington, DC: National Academies Press; 2002. http://www.nap.edu/catalog.php? record-id=10483. Accessed March 5, 2012.
31. Joellenbeck LM, Durch JS, Benet LZ, eds. Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures against Biological Warfare Agents; National Research Council. Giving Full Measure to Countermeasures: Addressing Problems in the DoD Program to Develop Medical Countermeasures Against Biological Warfare Agents. Washington, DC: National Academies Press; 2004. http://www.nap.edu/catalog.php?record-id=10908. AccessedMarch 5, 2012.
32. U.S. restructures $1.5B biodefense research effort. Global Security Newswire September 27, 2011. http://www.nti.org/gsn/article/us- restructures-15b-biodefense-research-effort/. Accessed March 5, 2012.
33. Hayden EC. Pentagon rethinks bioterror effort. Nature 2011 Sep 22;477(7365):380-381.
34. U.S. Centers for Disease Control and Prevention. Anthrax vaccine: what you need to know. March 10, 2010. http://www.cdc.gov/vaccines/pubs/vis/ downloads/vis-anthrax.pdf. Accessed March 5, 2012.
35. Merkel TJ, Perera PY, Kelly VK, et al. Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities. Proc Natl Acad Sci U S A 2010 Oct 19;107(42):18091-18096.
36. Lilly S. Getting Rich on Uncle Sucker: Should the Federal Government Strengthen Efforts to Fight Profiteering? Washintgon, DC: Center for American Progress; October 2010. http://www.americanprogress.org/issues/2010/10/pdf/ unclesucker.pdf. Accessed March 5, 2012.
37. Hylton WS. How ready are we for bioterrorism? New York Times Magazine October 26, 2011. http://www.nytimes.com/2011/10/30/magazine/how-ready-are-we- for-bioterrorism.html? pagewanted=all. Accessed March 5, 2012.
38. Roos R. VaxGen sells anthrax vaccine to rival firm. CIDRAP May 7, 2008.
39. Emergent BioSolutions awarded HHS contract valued at up to $186.6 million to develop rPA anthrax vaccine [press release]. September 17, 2010. Rockville, MD: Emergent Biosolutions.
40. Anthrax vaccine contract worth up to $1.25 billion over five years. Homeland Security News Wire October 6, 2011.
41. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology Nov 2010;156(Pt 11):3216-3223.
42. Jefferds MD, Laserson K, Fry AM, et al. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg Infect Dis Oct 2002;8(10):1138-1144. (Pubitemid 35257007)
43. Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis Oct 2002;8(10):1124-1132. (Pubitemid 35257005)
44. U.S. Centers for Disease Control and Prevention. Anthrax Q & A: preventive therapy. March 25, 2005. http://www.bt.cdc.gov/agent/anthrax/faq/ preventive.asp. Accessed January 10, 2012.
45. Office of Communications and Public Liaison, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Open Letter in Science Regarding NIH Biodefense Funding: Questions and Answers. March 17, 2005. http://www.niaid.nih.gov/news/newsreleases/2005/pages/scienceletter. aspx. Accessed March 5, 2012.
46. Smith BT, Mair M, Gronvall GK, Matheny J. Developing medical countermeasures for biodefense. Biosecur Bioterror Mar 2009;7(1):42-43.
47. Chemical Biological Radiological Nuclear Information Resource Center (CBRN IRC), CBMS. Fact Sheet: Recombinant Botulinum Toxin A/B Vaccine. July 8, 2010.
48. Chemical, Biological, Radiological, Nuclear Information Resource Center, (CBRN IRC), CBMS. Recombinant Plague Vaccine. July 19, 2010.
49. Chemical, Biological, Radiological, Nuclear Information Resource Center, (CBRN IRC), CBMS. Trivalent Filovirus Vaccine. November 26, 2010.
50. Gronvall GK, Bouri N. Biosafety laboratories. Biosecur Bioterror Dec 2008;6(4):299-307.
51. U.S. Government Accountability Office. High-Containment Laboratories: National Strategy for Oversight Is Needed. GAO-09-574. Washington, DC: U.S. Government Accountability Office; September 2009. http://www.gao.gov/new.items/ d09574.pdf. Accessed March 5, 2012.
52. Bhattacharjee Y. Planned Kansas biodefense laboratory over the rainbow? Science Insider February 14, 2012. http://news.sciencemag.org/scienceinsider/ 2012/02/planned-kansasbiodefense-lab.html. Accessed March 5, 2012.
53. NRC invites public comment on proposed MCMT&E facility [press release]. The Standard (Fort Detrick) March 17, 2011. http://www.detrick.army. mil/standard/entry.cfm?entry-id=ABDB79B 8-ED79-7A4E-3360383F69743143. Accessed March 5, 2012.
54. Weiss ML. Commissioning a biocontainment facility for accreditation/certification. Part 3: O&M and commissioning. ALN™ Magazine January 5, 2010.
55. U.S. Department of Defense. Department of Defense Directive: Use of Investigational New Drugs for Force Health Protection. Number 6200.2. Washington, DC: Department of Defense; 2000. http://www.med.navy.mil/bumed/human research/Documents/HRPP/Resources/ReferenceMaterial/1-09%20-%20DODD%206200- 2%20(1%20Aug%202000). pdf. Accessed March 5, 2012.
56. Department of Defense. Acceleration of Research, Development, and Production of Medical Countermeasures for Defense Against Biological Warfare Agents. Report to Congress required by P.L. 107-197, Section 1044(e). Washington, DC: Department of Defense; 2002.
57. Hayden EC. Biodefence since 9/11: the price of protection. Nature 2011 Sep 8;477(7363):150-152.
58. Human Genome Sciences. Human Genome Sciences announces new order for RAXIBACUMAB (ABTHRAX™) from U.S. government [press release]. Rockville, MD. July 22, 2009. http://www.hgsi.com/latest/human-genome-sciencesannounces- new-order-for-raxibacumab-abthrax-from-u.s.-govern. html. Accessed March 5, 2012.
59. Wizeman T, Altevogt BM, Claiborne AB; Forum on Drug Discovery, Development, and Translation; Forum on Medical and Public Health Preparedness for Catastrophic Events; Institute of Medicine. Advancing Regulatory Science for Medical Countermeasure Development: Workshop Summary.Washington, DC: National Academies Press; 2011. http://www.nap.edu/catalog.php?record-id=13173. Accessed March 5, 2012.
60. Omnibus Appropriations Act (PL 111-8), (2009).
61. Matishak M. Budget strips more than $600 million from Bioshield program. Global Security Newswire January 8, 2010. http://www.nti.org/gsn/ article/budget-strips-more-than-600-million-from-bioshield-program/. Accessed March 5, 2012.
62. Matishak M. WMD Commission says U.S. has failed to address bioterror threats. Global Security Newswire October 22, 2009. http://www.nti.org/gsn/ article/wmd-commission-says-ushas-failed-to-address-bioterror-threats/. Accessed March 5, 2012.
63. Hoyt K. Long Shot: Vaccines for National Defense. Cambridge, MA: Harvard University Press; 2012.
64. Roos R. BARDA: many biodefense products to mature within 5 years. CIDRAP October 6, 2011.
65. Hearing: Defending Against Public Health Threats. Subcommittee of the Committee of Appropriations. 111st session ed. Washington, DC; September 29, 2010.
66. Pentagon analyzing chem, bio defense programs. Global Security Newswire December 12, 2011. http://www.nti.org/gsn/article/pentagon-analyzing-chem-bio- defense-programs/. Accessed March 5, 2012.